FDA
-
-
-
-
-
-
-
Novocure Reports Third Quarter 2025 Financial Results
-
-
-
-
-
-
-
Zai Lab and Novocure Announce Results From the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting
-
-
-
-
-
-
-
Novocure (NVCR) Announces Preliminary Full Year and Fourth Quarter 2024 Performance and Provides Company Update
-
-
-
-
-
-
-
FDA Approves Novocure’s Optune Lua® for the Treatment of Metastatic Non-Small Cell Lung Cancer
-
-
-
-
-
-
-
Novocure Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update
-
-
-
-
-
-
-
Novocure Announces The Lancet Oncology Publishes Primary Data from Phase 3 LUNAR Clinical Trial in Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies
-
-
-
-
-
-
-
Zai Lab and Novocure Announce LUNAR Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lu
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

